Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 9/20 | 0.70 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CCND1 | P24385 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CDK7 | P50613 | 1/20 | 0.49 |
| ▸ | CCNH | P51946 | 1/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.49 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.49 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.47 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.46 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4192981 | 0.83 | MCL1 (0.60) | MCL1SLC40A1LMNAALDH1A1GLA | |
| SCHEMBL4190508 | 0.82 | MCL1 (0.67) | MCL1LMNAALDH1A1GLAL3MBTL1 | |
| SCHEMBL10702348 | 0.82 | MCL1 (0.70) | MCL1SLC40A1LMNAALDH1A1GLA | |
| SCHEMBL4192999 | 0.81 | ALPL (0.58) | MCL1SLC40A1ALDH1A1ERAP1 | |
| SCHEMBL30737433 | 0.78 | PTGES2 (0.56) | MCL1SLC40A1ALDH1A1PTGES2SLC22A12 | |
| SCHEMBL5605540 | 0.78 | SLC40A1 (0.64) | MCL1SLC40A1LMNAALDH1A1PTGES2 | |
| SCHEMBL13653282 | 0.77 | MCL1 (0.56) | MCL1LMNAALDH1A1GLAL3MBTL1 | |
| SCHEMBL13615259 | 0.76 | MCL1 (0.62) | MCL1LMNAALDH1A1GLAL3MBTL1 | |
| SCHEMBL5605439 | 0.76 | PTGES2 (0.52) | MCL1SLC40A1LMNAALDH1A1PTGES2 | |
| SCHEMBL30450095 | 0.75 | MCL1 (0.72) | MCL1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582673-B2 | Benzo[b]thiophene-2-sulfonic acid [2-(2-chloro-5-trifluoromethylbenzenesulfonylamino)phenyl] amide; agonists of GalR1; useful in treating neuropathic pain or cancer | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-09-01 | — | — | US | claimed |
| US-20060106089-A1 | Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use | VTVX HOLDINGS II LLC | 2006-05-18 | — | — | US | claimed |
| US-20090247536-A1 | Bissulfonamide Compounds As Agonists Of GalR1, Compositions, And Methods Of Use | MJALLI ADNAN M M | 2009-10-01 | — | — | US | disclosed |
| US-7582673-B2 | Benzo[b]thiophene-2-sulfonic acid [2-(2-chloro-5-trifluoromethylbenzenesulfonylamino)phenyl] amide; agonists of GalR1; useful in treating neuropathic pain or cancer | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1809619-A1 | BISSULFONAMIDE COMPOUNDS AS AGONISTS OF GALR1, COMPOSITIONS, AND METHODS OF USE | Transtech Pharma, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060106089-A1 | Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use | VTVX HOLDINGS II LLC | 2006-05-18 | — | — | US | disclosed |
| WO-2006047302-A1 | BISSULFONAMIDE COMPOUNDS AS AGONISTS OF GALR1, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106089-A1 | Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use | GALR1, GALR3, GALR2 | MCL1 2757/4885SLC40A1 4848/4885LMNA 1501/4885 |
| US-20090247536-A1 | Bissulfonamide Compounds As Agonists Of GalR1, Compositions, And Methods Of Use | GALR1, GALR3, GALR2 | MCL1 2757/4885SLC40A1 4848/4885LMNA 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.